Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the extension of indication “relief of broncho-obstructive symptoms in patients with chronic obstructive pulmonary disease”.
Clinical Benefit
| Substantial |
Le service médical rendu par ATIMOS 12 microgrammes/dose, solution pour inhalation en flacon pressurisé est important.
|
Clinical Added Value
| no clinical added value |
ATIMOS 12 microgrammes/dose, solution pour inhalation en flacon pressurisé n'apporte pas d'amélioration du service médical rendu (ASMR V) par rapport aux autres bronchodilatateurs de longue durée d'action disponibles dans cette indication.
|
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
C1MzCwb9JFTCK6yQ
